Answers are grounded in this paper and cite their sources.
Multimodality imaging differentiates cardiomyopathies, showing that mavacamten is a tolerable option for treatment.
Multimodality imaging is essential to differentiate primary obstructive HCM from HH-related cardiomyopathy. In this case, mavacamten was a well-tolerated alternative, though further data are needed to establish broader applicability.
No takes yet. Share an insight, caveat, or question.
Sam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: